Aflac Incorporated

(New York Stock Exchange)
Back to all articles
Slightly Bullish +25

JPMorgan raises target for Aflac stock from USD 116.00 to USD 119.00

Analyst upgrade AI-generated analysis

πŸ“ˆ Aflac reported second-quarter revenue of USD 4.22 billion, beating the USD 4.11 billion consensus estimate.

⚠️ Adjusted earnings per share of USD 1.75 missed the USD 1.76 analyst expectation despite strong revenue performance.

πŸ“‰ Revenue declined by 1.00 percent year-over-year compared to the prior quarter's USD 4.22 billion and higher EPS.

🏦 JPMorgan raised its price target for Aflac from USD 116.00 to USD 119.00 while retaining a Neutral rating.

πŸ“‰ Bank of America lowered its price target from USD 137.00 to USD 133.00 but kept its Buy rating intact.

🀝 The consensus analyst rating remains Hold with an average price target of USD 117.20 as of mid-October 2026.

πŸ“… Aflac is scheduled to report third-quarter 2026 results after market close on November 4, 2026.

🌏 The insurer operates in supplemental health and life insurance markets across the United States and Japan.

πŸ’° Aflac's market capitalization was valued at USD 59.3 billion as of October 15, 2026.

Bullish Signals
  • Aflac exceeded second-quarter revenue expectations with USD 4.22 billion reported against a consensus of USD 4.11 billion.
  • JPMorgan increased its price target for the stock from USD 116.00 to USD 119.00, indicating a constructive tilt in the analyst view.
Risk Factors
  • Adjusted earnings per share of USD 1.75 missed the USD 1.76 consensus estimate, signaling tighter margins.
  • Second-quarter revenue declined by 1.00 percent year-over-year compared to the prior quarter's performance.
  • Bank of America lowered its price target from USD 137.00 to USD 133.00 despite maintaining a Buy rating.
Full Analysis
Aflac Inc. reported second-quarter revenue of USD 4.22 billion, surpassing analyst expectations of USD 4.11 billion, though adjusted earnings per share of USD 1.75 slightly missed the USD 1.76 consensus. The company's revenue declined by 1.00 percent year-over-year to USD 4.22 billion, reflecting resilient demand but tighter earnings comparisons against the prior quarter where EPS was USD 1.78. Following the earnings release, analyst sentiment remains mixed regarding the stock's valuation and outlook. JPMorgan raised its price target for Aflac from USD 116.00 to USD 119.00 on October 15, 2026, citing a constructive tilt in the near-term picture despite headwinds, while retaining a Neutral rating. Conversely, Bank of America lowered its target from USD 137.00 to USD 133.00 but maintained a Buy rating. The market consensus for Aflac currently reflects a Hold rating with an average price target of USD 117.20 as of October 15, 2026. The insurer operates in the supplemental health and life insurance sectors across the United States and Japan, offering products ranging from accident and cancer coverage to critical illness and disability protection. Aflac is scheduled to release its third-quarter 2026 results after market close on November 4, 2026, followed by an investor webcast at 8:00 a.m. ET on November 5, 2026. The company's market capitalization stood at USD 59.3 billion as of October 15, 2026.